WKY Fatty Rat as a Model of Obesity and Non-insulin-dependent Diabetes Mellitus

The impact of glucagon to support postabsorptive glucose flux and glycemia in healthy rats and its attenuation in male Zucker diabetic fatty rats

Hyperglucagonemia is a hallmark of type 2 diabetes (T2DM), yet the role of elevated plasma glucagon (P-GCG) to promote excessive postabsorptive glucose production and contribute to hyperglycemia in patients with this disease remains debatable. We investigated the acute action of P-GCG to safeguard/support postabsorptive endogenous glucose production (EGP) and euglycemia in healthy Zucker control lean (ZCL) rats. Using male Zucker diabetic fatty (ZDF) rats that exhibit the typical metabolic disorders of human T2DM, such as excessive EGP, hyperglycemia, hyperinsulinemia, and hyperglucagonemia, we examined the ability of hyperglucagonemia to promote greater rates of postabsorptive EGP and hyperglycemia. Euglycemic or hyperglycemic basal insulin (INS-BC) and glucagon (GCG-BC) clamps were performed in the absence or during an acute setting of glucagon deficiency (GCG-DF, ∼10% of basal), either alone or in combination with insulin deficiency (INS-DF, ∼10% of basal). Glucose appearance, disappearance, and cycling rates were measured using [2-3H] and [3-3H]-glucose. In ZCL rats, GCG-DF reduced the levels of hepatic cyclic AMP, EGP, and plasma glucose (PG) by 50%, 32%, and 50%, respectively. EGP fell in the presence GCG-DF and INS-BC, but under GCG-DF and INS-DF, EGP and PG increased two- and threefold, respectively. GCG-DF revealed the hyperglucagonemia present in ZDF rats lacked the ability to regulate hepatic intracellular cyclic AMP levels and glucose flux, since EGP and PG levels fell by only 10%. We conclude that the liver in T2DM suffers from resistance to all three major regulatory factors, glucagon, insulin, and glucose, thus leading to a loss of metabolic flexibility.NEW & NOTEWORTHY In postabsorptive state, basal plasma insulin (P-INS) and plasma glucose (PG) act dominantly to increase hepatic glucose cycling and reduce endogenous glucose production (EGP) and PG in healthy rats, which is only counteracted by the acute action of basal plasma glucagon (P-GCG) to support EGP and euglycemia. Hyperglucagonemia, a hallmark of type 2 diabetes (T2DM) present in Zucker diabetic fatty (ZDF) rats, is not the primary mediator of hyperglycemia and high EGP as commonly thought; instead, the liver is resistant to glucagon as well as insulin and glucose.

ZDF fa/fa rats show increasing heterogeneity in main parameters during ageing as confirmed by biometrics, oxidative stress markers and MMP activity

NEW FINDINGS

What is the central question of this study? To characterize ZDF fa/fa rats and two controls (Wistar and lean ZDF fa/+) during ageing. What is the main finding and its importance? ZDF fa/fa rats with lower glycaemia have a greater body and left ventricular weight, and lower plasma gelatinase activity compared with hyperglycaemic rats. As diabetes represents a heterogeneous metabolic disorder, the inhomogeneity of ZDF fa/fa rats may be beneficial in the study of its different aspects. Our experiments may promote a discussion regarding the suitable normoglycemic control for aged ZDF fa/fa rats, especially in experiments focused on myocardial tissue.

ABSTRACT

Zucker diabetic fatty rats (ZDF fa/fa) - an animal model for the study of type 2 diabetes (T2D), are considered as a uniform group in most experimental studies; however, there are indices regarding their growing inhomogeneity over time. The main objective of our study was to monitor particular biometric and biochemical parameters of ZDF fa/fa rats during development to T2D and compare them with two controls (Wistar and lean ZDF fa/+). According to fasting glycaemia, ZDF fa/fa were arbitrarily split into two phenotypes - obese ZDF (fa/fa)-FAT and diabetic ZDF (fa/fa)-DIA. Glycaemia was progressively rising only in ZDF (fa/fa)-DIA which also exhibited higher cholesterol levels compared with ZDF (fa/fa)-FAT. In addition, ZDF (fa/fa)-FAT revealed more pronounced left ventricular hypertrophy and greater body weight, differentiating them from ZDF (fa/fa)-DIA. Moreover, we investigated the activity of matrix metalloproteinases (MMPs), multifunctional enzymes involved in tissue remodelling. Rats in the ZDF (fa/fa)-FAT group revealed lower plasma MMP-2 and MMP-9 activity compared with ZDF (fa/fa)-DIA. However, increased myocardial MMP-2 activity indicated left ventricular remodelling in both ZDF phenotypes. As T2D in humans represents a heterogeneous metabolic disorder, the heterogeneity of ZDF fa/fa rats may be beneficial in the study of different aspects of this pathology. Moreover, Wistar rats could serve as a more appropriate control for aged ZDF fa/fa rats than commonly used fa/+ rats that showed an increase in left ventricular weight, carbonyl stress markers in the left myocardium and MMP-2 activity in both ventricles, indicating heart remodelling processes compared with the Wistar control group. This article is protected by copyright. All rights reserved.

Peripheral Neuropathy Phenotyping in Rat Models of Type 2 Diabetes Mellitus: Evaluating Uptake of the Neurodiab Guidelines and Identifying Future Directions

Diabetic peripheral neuropathy (DPN) affects over half of type 2 diabetes mellitus (T2DM) patients, with an urgent need for effective pharmacotherapies. While many rat and mouse models of T2DM exist, the phenotyping of DPN has been challenging with inconsistencies across laboratories. To better characterize DPN in rodents, a consensus guideline was published in 2014 to accelerate the translation of preclinical findings. Here we review DPN phenotyping in rat models of T2DM against the 'Neurodiab' criteria to identify uptake of the guidelines and discuss how DPN phenotypes differ between models and according to diabetes duration and sex. A search of PubMed, Scopus and Web of Science databases identified 125 studies, categorised as either diet and/or chemically induced models or transgenic/spontaneous models of T2DM. The use of diet and chemically induced T2DM models has exceeded that of transgenic models in recent years, and the introduction of the Neurodiab guidelines has not appreciably increased the number of studies assessing all key DPN endpoints. Combined high-fat diet and low dose streptozotocin rat models are the most frequently used and well characterised. Overall, we recommend adherence to Neurodiab guidelines for creating better animal models of DPN to accelerate translation and drug development.

Diabetic Retinopathy: From Animal Models to Cellular Signaling

Diabetic retinopathy (DR) is an ocular complication of diabetes mellitus (DM), a metabolic disorder characterized by elevation in blood glucose level. The pathogenesis of DR includes vascular, neuronal, and inflammatory components leading to activation of complex cellular molecular signaling. If untreated, the disease can culminate in vision loss that eventually leads to blindness. Animal models mimicking different aspects of DM complications have been developed to study the development and progression of DR. Despite the significant contribution of the developed DR models to discovering the mechanisms of DR and the recent achievements in the research field, the sequence of cellular events in diabetic retinas is still under investigation. Partially, this is due to the complexity of molecular mechanisms, although the lack of availability of models that adequately mimic all the neurovascular pathobiological features observed in patients has also contributed to the delay in determining a precise molecular trigger. In this review, we provide an update on the status of animal models of DR to help investigators choose an appropriate system to validate their hypothesis. We also discuss the key cellular and physiological events of DR in these models.

alpha-Glucosidase inhibitors in diabetes: lessons from animal studies

Two rat models for non-insulin-dependent diabetes mellitus (NIDDM) have been used in our laboratory to study the effects of alpha-glucosidase inhibitors. These models become hyperglycaemic and have other characteristics which make them good models for NIDDM, and both prevention and reversal studies have been carried out; the prevention experiments were started before the animal became diabetic while the reversal groups were treated after diabetes had fully developed. In both models blood glucose was significantly lowered toward control levels using a dose of 40 mg per 100 g of diet while there was a less dramatic, but still significant, correction with half that dose. Treatment increased the weight gain of the more diabetic model (ZDF) while there was no effect of treatment on the weight of the Wistar diabetic fatty (WDF) rat. Other parameters such as glycated haemoglobins, nerve conduction velocity and nerve sugar content are also reversed with effective treatment of the hyperglycaemic condition.